Modality
Vaccine
MOA
SOS1i
Target
KRASG12D
Pathway
Complement
NSCLC
Development Pipeline
Preclinical
~May 2014
→ ~Aug 2015
Phase 1
~Nov 2015
→ ~Feb 2017
Phase 2
May 2017
→ May 2026
Phase 2Current
NCT03181860
2,929 pts·NSCLC
2017-05→2026-02·Recruiting
NCT04373684
1,630 pts·NSCLC
2018-08→2026-05·Not yet recruiting
4,559 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-022mo agoPh2 Data· NSCLC
2026-05-202mo awayPh2 Data· NSCLC
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P2
Recruit…
P2
Not yet…
Catalysts
Ph2 Data
2026-02-02 · 2mo ago
NSCLC
Ph2 Data
2026-05-20 · 2mo away
NSCLC
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03181860 | Phase 2 | NSCLC | Recruiting | 2929 | EDSS |
| NCT04373684 | Phase 2 | NSCLC | Not yet recr... | 1630 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF |